Glaucoma refers to a group of progressive eye conditions that lead to damage of the eye’s optic nerve, the nerve that carries visual information from the eye to the brain. In most cases, damage to the optic nerve is due to increased pressure in the eye, also known as intraocular pressure (IOP). Continued damage to the optic nerve from high IOP often leads to permanent loss of vision.
Blindness due to glaucoma is preventable if early treatment is effectively provided. First line treatment for most glaucoma patients is drug therapy, and prostaglandins are the most frequently prescribed initial drug therapy. Glaucoma drug therapies are delivered in the form of eye drops and lower IOP by either causing the eye to make less fluid or by helping fluid drain from the eye. If used correctly, these treatments can significantly lower IOP in patients. However, 30-50% of glaucoma patients are non-compliant with medical therapy and doctors perceive that this poor adherence leads to disease progression and loss of vision.
Ensuring patient adherence to ocular medications could significantly reduce preventable blindness and the number of glaucoma-related surgeries for these patients. Envisia is using the power of the PRINT® technology technology to create a next generation glaucoma treatment. Envisia’s lead product is a prostaglandin analogue that utilizes a proprietary, fully biodegradeable PRINT particle formulation to provide IOP reduction over many months, offering the potential to address the poor compliance that exists today and to significantly limit disease progression and vision loss.
The PRINT engineered particle technology offers a unique ability to design monodisperse particles or formulations of particles of large or small molecules in order to develop next generation ocular therapies. In addition to glaucoma, Envisia is exploring how this unique technology can address inflammation and other important ocular diseases.